Challenges in vascular tissue engineering for diabetic patients.

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Cardiovascular Research

Background:

• Diabetes mellitus, characterized by hyperglycemia and dyslipidemia, poses significant challenges for vascular tissue engineering.
• Diabetic conditions create an aggressive oxidative environment, leading to advanced glycation end products (AGEs) and increased vascular wall stiffness.
• Existing extracellular matrix (ECM)-based scaffolds are compromised in diabetes due to AGEs formation and impaired collagen degradation, affecting cellular interactions and leading to pathological remodeling.

Purpose of the Study:

• To review the impact of diabetes on vascular tissue engineering components and implant integration.
• To highlight the challenges posed by the diabetic milieu, including oxidative stress and ECM alterations.
• To propose strategies for enhancing the resilience of vascular grafts in diabetic patients.

Main Methods:

• Review of existing literature on diabetes, vascular tissue engineering, and biomaterial responses.
• Analysis of the effects of hyperglycemia, dyslipidemia, and AGEs on vascular cells and ECM.
• Evaluation of the potential of mesenchymal stem cells (MSCs) and antioxidant treatments.

Main Results:

• Diabetic conditions significantly alter ECM properties, increasing vascular stiffness and impairing tissue remodeling.
• Non-living vascular implants have limited lifespan in diabetic patients due to material degradation and lack of adaptation.
• Mesenchymal stem cells (MSCs) show promise due to their immunomodulatory effects, potentially protecting scaffolds from inflammation.

Conclusions:

• Vascular tissue engineering for diabetic patients requires careful consideration of the detrimental effects of the diabetic environment.
• Antioxidant treatments and the use of MSCs are promising strategies to mitigate diabetes-induced damage to vascular grafts.
• Testing of cells and scaffolds in diabetic animal models is crucial to validate their efficacy and resistance to diabetic complications.